Editas medicine stock price.

Nov 20, 2022 · Price as of December 1, 2023, 4:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street. Editas Medicine, Inc. Common Stock (EDIT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Robinhood (HOOD 5.91%), in particular, makes this process a breeze with its stock slices option (useful for weighting) and commission-free trading. Put simply, you …View live Editas Medicine, Inc. chart to track its stock's price action. Find market predictions, EDIT financials and market news.Consider, for instance, Editas Medicine (EDIT-6.20%) ... Stock Advisor list price is $199 per year. Join Stock Advisor Cumulative Growth of a $10,000 Investment in Stock Advisor.

Nov 20, 2022 · Price as of December 1, 2023, 4:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street.

Editas Medicine, Inc. (EDIT) Stock Price, Quote, News & Analysis EDIT Editas Medicine, Inc. Stock Price & Overview 38.49K followers $10.53 -0.08 ( -0.75%) …

Editas Medicine, Inc. Price and Consensus. ... Editas Medicine, Inc. (EDIT) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis ReportEditas Medicine (EDIT) Stock Price Performance. Editas Medicine (EDIT) Stock Key Data. ... Consensus Price Target is the stock price analysts expect to see within a …Nov 3, 2023 · Editas Medicine (EDIT) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.64. ... The sustainability of the stock's immediate price movement ... Editas Medicine Inc (NASDAQ: EDIT) has agreed to license its proprietary SLEEK (SeLection by Essential-gene Exon Knock-in) and AsCas12a gene editing technologies to Shoreline Biosciences.

What was the 52-week low for Editas Medicine stock? The low in the last 52 weeks of Editas Medicine stock was 6.08. According to the current price, Editas Medicine is 174.67% away from the 52-week ...

--Editas Medicine, Inc., a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per ...

Track Editas Medicine Inc (EDIT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsThe Motley Fool has positions in and recommends Beam Therapeutics, CRISPR Therapeutics, Caribou Biosciences, Editas Medicine, Intellia Therapeutics, and Vertex …Price as of November 22, 2023, 11:14 a.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street.Market Cap. $422M. Today's Change. (0.52%) $0.02. Current Price. $3.86. Price as of November 29, 2023, 4:00 p.m. ET. You’re reading a free article with opinions that may differ from The Motley ...Current Price. $10.65. Price as of November 27, 2023, 4:00 p.m. ET. Both are working on gene-editing therapies, with plenty of potential upside. But which is the better stock right now? You can't ...Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street.EDIT Editas Medicine Inc. 10.57 -0.15 ( -1.40%) Market Closed Delayed Prices By NASDAQ, in USD. Trade. Overview Chart Analysis News Stats.

Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus. Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing. CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a 30-day option to …Dec 1, 2023 · With Editas Medicine stock trading at $6.26 per share, the total value of Editas Medicine stock (market capitalization) is $511.02M. Editas Medicine stock was originally listed at a price of $18.20 in Feb 3, 2016. Find out the direct holders, institutional holders and mutual fund holders for Editas Medicine, Inc. (EDIT).CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share, before deducting underwriter discounts and …Check out our EDIT stock analysis, current EDIT quote, charts, and historical prices for Editas Medicine stock With Editas Medicine stock trading at $6.26 per share, the total value of Editas Medicine stock (market capitalization) is $511.02M. Editas Medicine stock was originally listed at a price of $18.20 in Feb 3, 2016.

Current Price. $10.49. Price as of November 22, 2023, 4:00 p.m. ET. Both are working on gene-editing therapies, with plenty of potential upside. But which is the better stock right now? You can't ...

Shares of Editas Medicine ( EDIT 11.39%) were skyrocketing 41.5% higher as of 11:57 a.m. EST on Monday. The company didn't announce any big news over the weekend or today, so why is the stock ...Insider Monkey’s database tracked Editas Medicine, Inc. (NASDAQ:EDIT) in 8 billionaire portfolios at the end of March. It is one of the top DNA stocks to monitor.This might seem like deja vu. Editas Medicine ( EDIT 11.39%) shares soared on Monday. Then on Tuesday. And on Wednesday. The stock is on fire again today, skyrocketing 22.3% as of 11:09 a.m. EST ...Find out the direct holders, institutional holders and mutual fund holders for Editas Medicine, Inc. (EDIT).Find the latest Editas Medicine, Inc. (8EM.F) stock quote, history, news and other vital information to help you with your stock trading and investing.Price is a widely used stock evaluation measure. Find the latest Price for Editas Medicine (EDIT) ... Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates 11/03/23-7:45AM EST ZacksNov 17, 2023 · Get Editas Medicine Inc (EDIT.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments

Editas Medicine stock price prediction is an act of determining the future value of Editas Medicine shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Editas Medicine's future price could yield a significant profit.

11.34%. Get the latest Editas Medicine Inc (EDIT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...

Track Editas Medicine Inc (EDIT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...Get the latest Editas Medicine, Inc. (EDIT) stock news and headlines to help you in your trading and investing decisions. What was the 52-week low for Editas Medicine stock? The low in the last 52 weeks of Editas Medicine stock was 6.08. According to the current price, Editas Medicine is 174.67% away from the 52-week ...CAMBRIDGE, Mass. and SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it has entered into a definitive agreement with Shoreline Biosciences (Shoreline) for Shoreline to license Editas Medicine’s proprietary SLEEK (SeLection by …Editas Medicine, Inc. Common Stock (EDIT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Gene editing stocks rallied Thursday as Wall Street took notice of the underperforming subsector issuing a series of bullish views despite recent selloff. Read more here.Recent reports have lowered Editas Medicine’s price target from $36.00 to $30.00 and raised it from $13.00 to $15.00. Editas Medicine’s stock opened at $6.71 and has a 50-day moving average of $8.70 and a 200-day moving average of $9.86. The company’s market capitalization is $462.79 million, and it has a PE ratio of -2.09 and a …Price of Stock Editas Medicine (EDIT) Today.

13 Okt 2023 ... Today's Editas Medicine Inc. Share Price - Explore EDIT stock Information, latest price chart, peers growth, market trend and start ...Find out the direct holders, institutional holders and mutual fund holders for Editas Medicine, Inc. (EDIT).Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...Instagram:https://instagram. indexsp spdaudpvanguard emerging markets bond fundnasdaq xwelbest nft investments Another Jennifer Doudna co-founded company is Editas Medicine (NASDAQ: EDIT). Like Intellia, Editas is among the gene editing stocks using CRISPR/Cas9 systems to to solve incurable diseases. vnq stock dividendwalmart dividends Nov 20, 2023 · The average price target on the stock implies a 67% gain over the next 12 months. ... The past month has been a great one for Editas Medicine (EDIT 0.86%), but the stock is still down about 89% ... yield on 5 year treasury Apr 3, 2023 · Current Price. $10.58. Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ... A cough can be annoying, and it can affect you day and night. There are many cough medicines available over-the-counter but it’s hard to know which one is the best to alleviate your symptoms. This article will help break down the best over-...